Free Trial
→ Social Security’s trust fund runs short in 2032. Guess who controls Congress. (From Priority Gold) (Ad)tc pixel Free MTRI Stock Alerts

Mentari Therapeutics (MTRI) Financials

Mentari Therapeutics logo
$12.20 -3.80 (-23.75%)
As of 11/10/2026 03:59 PM Eastern
Annual Income Statements for Mentari Therapeutics

Annual Income Statements for Mentari Therapeutics

This table shows Mentari Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.36 -9.77 -19 -7.95 -7.68 -8.16 -13
Consolidated Net Income / (Loss)		 -8.94 -10 -19 -7.95 -7.68 -8.16 -13
Net Income / (Loss) Continuing Operations		 -8.94 -10 -19 -7.95 -7.74 -8.69 -11
Total Pre-Tax Income 		-9.02 -10 -19 -7.93 -7.67 -8.69 -11
Total Operating Income		 -9.15 -9.94 -17 -8.38 -8.13 -8.47 -12
Total Gross Profit		 0.00 0.00 0.54 1.40 1.10 0.00 0.00
Total Revenue		 0.00 0.00 1.09 4.14 4.60 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.55 2.73 3.50 0.00 0.00
Total Operating Expenses		 9.15 9.94 18 9.78 9.24 8.47 12
Selling, General & Admin Expense		 3.23 4.48 6.87 5.85 5.80 5.41 6.66
Research & Development Expense		 5.81 5.34 7.28 3.73 3.22 2.82 3.03
Depreciation Expense		 0.11 0.12 0.19 0.20 0.22 0.21 0.21
Other Operating Expenses / (Income)		 - - - - - 0.03 0.06
Impairment Charge		 - - 3.47 - - 0.00 1.65
Other Special Charges / (Income)		 - - - - - 0.00 0.01
Total Other Income / (Expense), net		 0.13 -0.10 -1.34 0.44 0.53 -0.22 0.23
Interest & Investment Income		 0.13 0.02 0.10 0.49 0.53 0.16 0.24
Other Income / (Expense), net		 0.00 0.24 -1.43 -0.05 0.00 -0.37 -0.01
Income Tax Expense		 - - 0.00 0.01 0.01 0.00 0.00
Net Income / (Loss) Discontinued Operations		 - - - - - 0.53 -1.19
Preferred Stock Dividends Declared		 - - - - - 0.00 0.43
Basic Earnings per Share		 ($1.71) ($37.96) ($33.17) ($3.25) ($20.14) ($8.36) ($3.12)
Weighted Average Basic Shares Outstanding		 - 9.38M 560.83K 2.45M 381.05K 975.90K 4.16M
Diluted Earnings per Share		 ($1.71) - - - ($20.14) ($8.36) ($3.12)
Weighted Average Diluted Shares Outstanding		 5.22M 268.79K 908.76K - 381.05K 975.90K 4.16M
Weighted Average Basic & Diluted Shares Outstanding		 - 9.38M 908.76K - - 2.38M 5.49M

Quarterly Income Statements for Mentari Therapeutics

This table shows Mentari Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.72 -1.94 -1.68 -2.58 -2.12 -1.79 -1.73 -2.03 -2.97 -6.27 -2.33
Consolidated Net Income / (Loss)		 -1.72 -1.94 -1.68 -2.58 -2.12 -1.79 -1.73 -2.03 -2.97 -5.84 -2.33
Net Income / (Loss) Continuing Operations		 -1.72 -2.00 -1.68 -2.58 -2.07 -2.37 -1.83 -2.01 -2.79 -4.84 -2.00
Total Pre-Tax Income 		-1.72 -1.93 -1.68 -2.58 -2.07 -2.37 -1.83 -2.03 -2.79 -4.83 -2.00
Total Operating Income		 -1.80 -2.01 -1.75 -2.21 -2.06 -2.45 -1.92 -2.12 -2.82 -4.91 -2.01
Total Gross Profit		 0.29 0.47 0.49 0.46 0.00 -0.95 0.00 0.18 0.00 -0.59 0.00
Total Revenue		 1.17 1.28 1.26 1.11 0.00 -2.38 0.00 0.82 0.00 -1.94 0.00
Total Cost of Revenue		 0.88 0.82 0.77 0.65 0.00 -1.42 0.00 0.64 0.00 -1.35 0.00
Total Operating Expenses		 2.09 2.48 2.25 2.67 2.06 1.50 1.92 2.30 2.82 4.32 2.01
Selling, General & Admin Expense		 1.37 1.76 1.49 1.72 1.58 0.62 1.24 1.62 1.74 1.77 1.80
Research & Development Expense		 0.66 0.66 0.70 0.90 0.43 0.80 0.58 0.63 1.02 0.79 0.21
Depreciation Expense		 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00
Other Operating Expenses / (Income)		 - - - - - - 0.06 - - - -0.00
Total Other Income / (Expense), net		 0.07 0.14 0.08 -0.37 -0.01 0.08 0.09 0.07 0.02 0.10 0.01
Interest & Investment Income		 0.12 0.10 0.06 0.03 0.02 0.05 0.09 0.07 0.05 0.03 0.01
Income Tax Expense		 0.00 0.01 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Net Income / (Loss) Discontinued Operations		 - - - - -0.05 - 0.10 - -0.17 - -0.34
Basic Earnings per Share		 ($3.58) ($5.09) ($2.71) ($3.64) ($1.94) ($1.83) ($0.44) ($0.51) ($0.73) ($1.51) ($0.42)
Weighted Average Basic Shares Outstanding		 480.65K 381.05K 620.13K 706.55K 1.10M 975.90K 3.95M 3.95M 4.05M 4.16M 5.47M
Diluted Earnings per Share		 ($3.58) ($5.09) ($2.71) ($3.64) ($1.94) ($1.83) ($0.44) ($0.51) ($0.73) ($1.51) ($0.42)
Weighted Average Diluted Shares Outstanding		 480.65K 381.05K 620.13K 706.55K 1.10M 975.90K 3.95M 3.95M 4.05M 4.16M 5.47M
Weighted Average Basic & Diluted Shares Outstanding		 8.36M 0.00 718.03K 1.21M 1.21M 2.38M 2.80M 2.92M 3.31M 5.49M 5.49M

Annual Cash Flow Statements for Mentari Therapeutics

This table details how cash moves in and out of Mentari Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Change in Cash & Equivalents		 -3.62 1.56 -1.19 2.74 -2.34 4.17 -8.55
Net Cash From Operating Activities		 -7.37 -9.79 -16 -7.28 -6.99 -8.10 -8.64
Net Cash From Continuing Operating Activities		 -7.37 -9.70 -16 -7.28 -6.98 -7.92 -10
Net Income / (Loss) Continuing Operations		 -8.94 -10 -19 -7.95 -7.68 -8.16 -13
Consolidated Net Income / (Loss)		 -8.94 -10 -19 -7.95 -7.68 -8.16 -13
Depreciation Expense		 0.11 0.12 0.19 0.20 0.22 0.21 0.21
Amortization Expense		 - 0.11 0.33 0.39 0.38 0.32 0.50
Non-Cash Adjustments To Reconcile Net Income		 1.09 0.73 5.24 0.21 0.06 -0.23 1.02
Changes in Operating Assets and Liabilities, net		 0.36 -0.45 -2.73 -0.14 0.03 -0.05 0.67
Net Cash From Discontinued Operating Activities		 - - - - - -0.18 1.52
Net Cash From Investing Activities		 3.79 -0.00 -0.67 -0.66 -0.01 0.00 0.00
Net Cash From Continuing Investing Activities		 3.79 -0.00 -0.67 -0.66 -0.01 0.00 0.00
Purchase of Investments		 -0.04 - - -0.04 -0.04 -0.04 -0.04
Sale and/or Maturity of Investments		 3.88 - 0.00 0.04 0.04 0.04 0.04
Net Cash From Financing Activities		 -0.03 11 15 11 4.65 12 0.09
Net Cash From Continuing Financing Activities		 -0.03 11 15 11 4.65 12 0.09
Repurchase of Common Equity		 - - - - -0.56 -0.88 -0.14
Issuance of Common Equity		 0.00 12 17 11 5.22 8.13 0.23
Other Financing Activities, net		 - - - 0.00 0.00 5.02 0.00
Cash Interest Paid		 - - - 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 - - 0.00 0.01 0.01 0.00 0.00

Quarterly Cash Flow Statements for Mentari Therapeutics

This table details how cash moves in and out of Mentari Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 -1.93 -1.03 -0.99 -2.16 1.26 6.06 -2.07 -2.38 -1.46 -2.96 -1.10
Net Cash From Operating Activities		 -1.93 -1.03 -1.83 -2.50 -1.66 -2.11 -1.93 -2.38 -1.70 -2.96 -1.14
Net Cash From Continuing Operating Activities		 -1.94 -1.03 -1.83 -2.50 -2.23 -1.36 -1.91 -2.38 -3.02 -3.15 -1.21
Net Income / (Loss) Continuing Operations		 -1.72 -1.94 -1.68 -2.58 -2.12 -1.79 -1.73 -2.03 -2.97 -5.84 -2.33
Consolidated Net Income / (Loss)		 -1.72 -1.94 -1.68 -2.58 -2.12 -1.79 -1.73 -2.03 -2.97 -5.84 -2.33
Depreciation Expense		 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00
Amortization Expense		 - 0.10 0.09 0.08 0.08 0.08 0.10 0.10 0.08 0.21 0.22
Non-Cash Adjustments To Reconcile Net Income		 -0.23 -0.02 -0.07 -0.06 -0.05 -0.06 -0.09 -0.01 -0.12 1.24 0.02
Changes in Operating Assets and Liabilities, net		 -0.32 0.77 -0.22 0.00 -0.19 0.36 -0.26 -0.49 -0.07 1.19 0.88
Net Cash From Discontinued Operating Activities		 - - - - - -0.75 -0.02 - - 0.19 0.07
Net Cash From Investing Activities		 -0.00 - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 -0.00 - 0.00 - - - 0.00 - - - 0.00
Purchase of Investments		 -0.02 0.00 -0.02 -0.00 -0.02 -0.00 -0.02 -0.00 -0.02 0.00 0.00
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.00
Sale and/or Maturity of Investments		 0.02 -0.00 0.02 0.00 0.02 0.00 0.02 0.00 0.02 -0.00 0.00
Net Cash From Financing Activities		 - 0.00 0.84 0.34 2.92 8.17 -0.14 - 0.23 -0.00 0.04
Net Cash From Continuing Financing Activities		 - 0.00 0.84 0.34 2.92 8.17 -0.14 - 0.23 -0.00 0.04
Repurchase of Common Equity		 - - -0.19 -0.06 -0.02 -0.62 -0.14 - - -0.00 0.00
Other Financing Activities, net		 - - - - - - 0.00 - - - 0.04
Cash Interest Paid		 - - 0.00 - - - 0.00 - - - 0.00
Cash Income Taxes Paid		 - 0.01 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for Mentari Therapeutics

This table presents Mentari Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Total Assets		 7.80 9.78 13 14 12 16 3.03
Total Current Assets		 6.31 8.38 9.60 11 8.69 13 2.68
Cash & Equivalents		 5.81 7.36 6.18 8.91 6.57 11 2.19
Short-Term Investments		 0.04 0.05 0.04 0.04 0.04 0.04 0.04
Prepaid Expenses		 0.42 0.96 0.80 0.50 0.48 0.32 0.24
Other Current Assets		 - - - - - 0.00 0.02
Other Current Nonoperating Assets		 - - - - - 1.76 0.18
Plant, Property, & Equipment, net		 0.40 0.33 0.90 0.72 1.25 0.99 0.22
Total Noncurrent Assets		 1.09 1.08 2.29 2.05 1.88 1.72 0.13
Other Noncurrent Operating Assets		 0.00 0.01 0.18 0.10 0.10 0.10 0.13
Total Liabilities & Shareholders' Equity		 7.80 9.78 13 14 12 16 3.03
Total Liabilities		 1.92 2.40 3.71 2.02 2.62 2.15 1.96
Total Current Liabilities		 1.68 2.22 3.32 2.00 1.97 1.84 1.96
Accounts Payable		 1.61 2.13 2.42 1.61 1.65 1.23 1.84
Other Current Nonoperating Liabilities		 - - - - - 0.17 0.11
Total Noncurrent Liabilities		 0.25 0.19 0.39 0.02 0.64 0.31 0.00
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.88 7.38 9.08 12 9.21 13 1.08
Total Preferred & Common Equity		 5.88 7.38 9.08 12 9.21 13 1.08
Total Common Equity		 5.88 7.38 9.08 12 9.21 13 1.08
Common Stock		 71 82 102 113 118 131 131
Retained Earnings		 -65 -75 -93 -101 -109 -117 -130
Accumulated Other Comprehensive Income / (Loss)		 -0.30 0.13 0.13 0.13 0.13 0.13 0.13

Quarterly Balance Sheets for Mentari Therapeutics

This table presents Mentari Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026 Q1 2027
Period end date 12/31/2023 3/31/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026 9/30/2026
Total Assets		 15 13 10 8.50 9.28 13 11 9.13 1.31
Total Current Assets		 12 10 7.28 5.47 6.41 11 8.79 6.89 1.26
Cash & Equivalents		 9.53 7.60 5.58 3.42 4.68 9.33 6.95 5.16 1.09
Short-Term Investments		 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04
Prepaid Expenses		 1.11 1.02 0.15 0.64 0.51 0.19 0.66 0.62 0.10
Other Current Assets		 - - - - - - - - 0.02
Other Current Nonoperating Assets		 - - - - - - - 1.07 0.01
Plant, Property, & Equipment, net		 1.48 1.37 1.34 1.23 1.11 0.88 0.76 0.64 0.00
Total Noncurrent Assets		 1.96 1.92 1.84 1.80 1.76 1.68 1.64 1.60 0.04
Other Noncurrent Operating Assets		 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.04
Total Liabilities & Shareholders' Equity		 15 13 10 8.50 9.28 13 11 9.13 1.31
Total Liabilities		 2.48 2.25 2.07 2.32 2.26 1.77 1.60 2.24 2.51
Total Current Liabilities		 1.68 1.53 1.44 1.79 1.84 1.55 1.48 2.21 2.51
Accounts Payable		 1.29 1.18 1.01 1.37 1.41 1.13 1.07 1.01 2.49
Other Current Nonoperating Liabilities		 - - - - - - - 0.81 0.01
Total Noncurrent Liabilities		 0.80 0.73 0.63 0.53 0.42 0.22 0.12 0.03 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 13 11 8.40 6.18 7.02 12 9.59 6.89 -1.20
Total Preferred & Common Equity		 13 11 8.40 6.18 7.02 12 9.59 6.89 -1.20
Total Common Equity		 13 11 8.40 6.18 7.02 12 9.59 6.89 -1.20
Common Stock		 118 118 119 119 122 130 130 131 131
Retained Earnings		 -105 -107 -111 -113 -115 -119 -121 -124 -133
Accumulated Other Comprehensive Income / (Loss)		 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13

Annual Metrics And Ratios for Mentari Therapeutics

This table displays calculated financial ratios and metrics derived from Mentari Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
DEI Shares Outstanding		 0.00 8,050,707.00 14,641,645.00 3,328,191.00 6,056,970.00 6,056,970.00 6,056,970.00
DEI Adjusted Shares Outstanding		 0.00 16,101.00 29,283.00 166,410.00 302,849.00 302,849.00 302,849.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -606.96 -635.18 -47.76 -25.34 -26.95 -42.90
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 279.61% 11.18% -100.00% 0.00%
EBITDA Growth		 0.00% -4.74% -92.08% 56.94% 3.84% -10.38% -31.26%
EBIT Growth		 0.00% -5.95% -92.83% 54.93% 3.47% -8.75% -31.33%
NOPAT Growth		 0.00% -8.60% -73.72% 51.47% 2.92% -4.18% -36.97%
Net Income Growth		 0.00% -14.14% -82.30% 57.27% 3.42% -6.34% -53.89%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 58.49% 62.68%
Operating Cash Flow Growth		 0.00% -32.76% -59.17% 53.26% 4.08% -15.94% -6.72%
Free Cash Flow Firm Growth		 0.00% 0.00% -116.36% 65.40% -7.80% 29.74% -36.16%
Invested Capital Growth		 0.00% 685.89% 1,441.98% -13.75% 2.78% -57.79% -189.95%
Revenue Q/Q Growth		 0.00% 0.00% 89.57% 76.79% -18.27% -100.00% -100.00%
EBITDA Q/Q Growth		 0.00% -17.27% -33.27% 43.19% -24.71% -6.00% -35.24%
EBIT Q/Q Growth		 0.00% -18.35% -33.06% 41.41% -22.48% -5.36% -34.37%
NOPAT Q/Q Growth		 0.00% -21.32% -22.87% 41.74% -22.48% -5.52% -35.02%
Net Income Q/Q Growth		 0.00% -19.19% -32.96% 48.66% -26.32% 1.80% -47.61%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -26.32% -10.29% -48.57%
Operating Cash Flow Q/Q Growth		 0.00% -6.62% -15.07% 31.76% -5.61% -15.42% -15.90%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -11.56% 31.56% 10.23% 4.19% -17.19%
Invested Capital Q/Q Growth		 0.00% -74.11% -26.57% 14.90% -28.59% -56.63% -166.36%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 49.89% 33.93% 23.94% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% -1,669.16% -189.36% -163.77% 0.00% 0.00%
Operating Margin		 0.00% 0.00% -1,584.71% -202.60% -176.92% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% -1,716.14% -203.77% -176.92% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% -1,707.32% -192.18% -166.94% 0.00% 0.00%
Tax Burden Percent		 99.09% 101.62% 100.00% 100.17% 100.09% 93.92% 110.44%
Interest Burden Percent		 98.58% 103.55% 99.49% 94.16% 94.27% 98.24% 97.89%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -621.76% -172.52% -178.36% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -518.08% -143.53% -151.78% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 395.68% 97.43% 106.27% 0.00% 0.00%
Return on Equity (ROE)		 -152.07% -153.95% -226.07% -75.09% -72.09% -72.10% -173.14%
Cash Return on Invested Capital (CROIC)		 0.00% -5,368.37% -797.39% -157.76% -181.10% -176.52% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -165.68% -62.67% -62.74% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -164.83% -59.10% -59.20% 0.00% 0.00%
Return on Common Equity (ROCE)		 -152.07% -153.95% -226.07% -75.09% -72.09% -72.10% -173.14%
Return on Equity Simple (ROE_SIMPLE)		 -152.07% -138.32% -204.88% -65.74% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.41 -6.96 -12 -5.87 -5.69 -5.93 -8.13
NOPAT Margin		 0.00% 0.00% -1,109.29% -141.82% -123.85% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -43.32% -49.99% -103.68% -28.99% -26.58% -24.72% -61.73%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -57.80% -43.17% -755.83%
Cost of Revenue to Revenue		 0.00% 0.00% 50.11% 66.07% 76.06% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 630.33% 141.40% 126.11% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 668.48% 90.24% 69.98% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 1,634.60% 236.53% 200.87% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.15 -9.70 -19 -8.43 -8.13 -8.85 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.04 -9.47 -18 -7.83 -7.53 -8.31 -11
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 3.47 0.76 0.26 0.17 0.24 6.00
Price to Tangible Book Value (P/TBV)		 0.00 4.05 0.99 0.30 0.22 0.27 6.00
Price to Revenue (P/Rev)		 0.00 0.00 6.32 0.75 0.35 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 77.98 0.40 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 1.34 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.04 0.09 0.00 0.07 0.02 0.00
Long-Term Debt to Equity		 0.00 0.03 0.04 0.00 0.07 0.02 0.00
Financial Leverage		 -0.99 -0.98 -0.76 -0.68 -0.70 -0.80 -0.99
Leverage Ratio		 1.33 1.33 1.37 1.27 1.22 1.21 1.28
Compound Leverage Factor		 1.31 1.37 1.36 1.20 1.15 1.19 1.26
Debt to Total Capital		 0.00% 3.53% 8.04% 0.13% 6.55% 2.23% 0.00%
Short-Term Debt to Total Capital		 0.00% 1.05% 4.10% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 2.48% 3.95% 0.13% 6.55% 2.23% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 96.47% 91.96% 99.87% 93.45% 97.77% 100.00%
Debt to EBITDA		 0.00 -0.03 -0.04 0.00 -0.09 -0.04 0.00
Net Debt to EBITDA		 0.00 0.75 0.30 1.14 0.79 1.26 0.00
Long-Term Debt to EBITDA		 0.00 -0.02 -0.02 0.00 -0.09 -0.04 0.00
Debt to NOPAT		 0.00 -0.04 -0.07 0.00 -0.11 -0.05 0.00
Net Debt to NOPAT		 0.00 1.03 0.45 1.52 1.05 1.77 0.00
Long-Term Debt to NOPAT		 0.00 -0.03 -0.03 0.00 -0.11 -0.05 0.00
Altman Z-Score		 0.00 -6.84 -13.27 -10.03 -13.75 -10.67 -70.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 3.77 3.78 2.89 5.66 4.41 6.99 1.37
Quick Ratio		 3.52 3.35 1.90 4.61 3.53 5.86 1.14
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -7.16 -15 -5.36 -5.78 -4.06 -5.53
Operating Cash Flow to CapEx		 -17,545.38% -567,573.33% -39,848.01% -4,551.60% -75,173.06% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -19.88 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -27.17 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -27.17 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.10 0.31 0.35 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 21.80 23.74 15.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 1.33 2.44 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 1.77 5.08 4.66 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.24 1.36 2.14 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 16.74 15.38 24.34 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 274.31 149.30 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 1,521.19 268.76 170.28 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 -1,504.45 20.93 3.36 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.03 0.24 3.65 3.15 3.24 1.37 -1.23
Invested Capital Turnover		 0.00 0.00 0.56 1.22 1.44 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.21 3.41 -0.50 0.09 -1.87 -2.59
Enterprise Value (EV)		 0.00 18 1.46 -5.86 -4.36 -7.31 4.22
Market Capitalization		 0.00 26 6.89 3.08 1.61 3.17 6.45
Book Value per Share		 $1.13 $0.92 $0.62 $3.63 $24.16 $13.77 $0.26
Tangible Book Value per Share		 $0.92 $0.78 $0.48 $3.05 $19.48 $12.11 $0.26
Total Capital		 5.88 7.65 9.87 12 9.85 14 1.08
Total Debt		 0.00 0.27 0.79 0.02 0.64 0.31 0.00
Total Long-Term Debt		 0.00 0.19 0.39 0.02 0.64 0.31 0.00
Net Debt		 -5.85 -7.14 -5.43 -8.94 -5.97 -10 -2.23
Capital Expenditures (CapEx)		 0.04 0.00 0.04 0.16 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.21 -1.17 0.46 0.37 0.10 0.24 -1.51
Debt-free Net Working Capital (DFNWC)		 4.64 6.24 6.68 9.33 6.72 11 0.72
Net Working Capital (NWC)		 4.64 6.16 6.28 9.33 6.72 11 0.72
Net Nonoperating Expense (NNE)		 2.53 3.25 6.52 2.08 1.98 2.23 4.44
Net Nonoperating Obligations (NNO)		 -5.85 -7.14 -5.43 -8.94 -5.97 -12 -2.30
Total Depreciation and Amortization (D&A)		 0.11 0.23 0.51 0.60 0.60 0.53 0.71
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 42.30% 9.05% 2.24% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 613.39% 225.63% 146.11% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 576.28% 225.63% 146.11% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($38.00) ($33.17) ($3.25) ($20.20) ($8.36) ($3.12)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 375.08K 908.76K 2.45M 381.05K 975.99K 4.16M
Adjusted Diluted Earnings per Share		 $0.00 ($38.00) $0.00 $0.00 $0.00 ($8.36) ($3.12)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 268.79K 560.83K 0.00 0.00 975.99K 4.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($38.00) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 375.08K 908.76K 0.00 0.00 2.38M 5.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.41 -6.96 -9.65 -5.87 -5.69 -5.93 -6.97
Normalized NOPAT Margin		 0.00% 0.00% -886.17% -141.82% -123.85% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% -1,707.32% -191.86% -166.79% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 -26.91 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -19.31 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -26.91 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -19.31 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -7.32% -10.83% -1.09%

Quarterly Metrics And Ratios for Mentari Therapeutics

This table displays calculated financial ratios and metrics derived from Mentari Therapeutics' official financial filings.

Metric Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 6,056,970.00 6,056,970.00 6,056,970.00 6,056,970.00 6,056,970.00 6,056,970.00 6,056,970.00 6,056,970.00 6,056,970.00 6,056,970.00 5,493,735.00
DEI Adjusted Shares Outstanding		 302,849.00 302,849.00 302,849.00 302,849.00 302,849.00 302,849.00 302,849.00 302,849.00 302,849.00 302,849.00 5,493,735.00
DEI Earnings Per Adjusted Shares Outstanding		 -5.69 -6.40 -5.54 -8.50 -7.00 -5.91 -5.70 -6.70 -9.79 -20.71 -0.42
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 13.41% -44.48% 40.23% -10.36% -100.00% -285.21% -100.00% -26.22% 0.00% 18.35% 0.00%
EBITDA Growth		 10.52% -398.35% 36.99% -55.78% -9.19% -25.85% -11.16% 20.75% -38.48% -99.79% -1.18%
EBIT Growth		 14.19% -282.03% 35.09% -58.40% -12.98% -22.80% -10.90% 18.61% -36.28% -99.72% -4.43%
NOPAT Growth		 16.43% -289.14% 33.16% -29.41% -14.77% -22.08% -9.68% 3.88% -36.62% -100.06% -4.43%
Net Income Growth		 13.77% -472.61% 33.86% -74.20% -23.10% 7.71% -2.92% 21.23% -39.86% -226.53% -34.97%
EPS Growth		 0.00% -472.61% 33.86% 1.89% 45.81% 64.05% 83.76% 85.99% 62.37% 17.49% 4.55%
Operating Cash Flow Growth		 -16.76% -56.42% 15.98% -35.39% 14.21% -105.11% -5.69% 5.03% -2.15% -40.44% 40.84%
Free Cash Flow Firm Growth		 -519.53% -1,163.37% 2.66% 68.48% 98.00% 110.28% 102.13% -9.39% -1,003.63% -647.27% 6,870.53%
Invested Capital Growth		 65.36% 2.78% 36.84% -15.80% -30.50% -57.79% -36.45% -14.95% -41.22% -189.95% -195.97%
Revenue Q/Q Growth		 -5.45% 9.42% -1.44% -12.09% -100.00% 0.00% 100.00% -26.78% -100.00% 0.00% 100.00%
EBITDA Q/Q Growth		 -12.57% -1.73% 12.66% -55.76% 21.10% -17.24% 22.85% -17.95% -37.87% -69.14% 60.93%
EBIT Q/Q Growth		 -12.12% -6.94% 12.03% -50.18% 20.03% -16.24% 20.56% -16.48% -33.89% -70.35% 58.46%
NOPAT Q/Q Growth		 -5.36% -11.85% 12.68% -25.76% 6.56% -18.98% 21.55% -20.25% -32.80% -74.22% 59.05%
Net Income Q/Q Growth		 -16.55% -12.47% 13.41% -53.47% 17.63% 15.68% 3.43% -17.45% -46.25% -96.86% 60.09%
EPS Q/Q Growth		 -16.55% -12.47% 13.41% -34.32% 46.70% 5.67% 75.96% -15.91% -43.14% -106.85% 72.19%
Operating Cash Flow Q/Q Growth		 -4.66% 46.79% -77.50% -36.97% 33.68% -27.20% 8.53% -47.81% 28.66% -74.88% 61.47%
Free Cash Flow Firm Q/Q Growth		 -12.34% 51.00% -51.18% 62.12% 92.87% 351.67% -68.60% -682.99% 28.07% -24.80% 499.97%
Invested Capital Q/Q Growth		 3.94% -28.59% 18.26% -4.09% -14.20% -56.63% 78.06% 28.37% -40.70% -166.36% -89.98%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 24.69% 36.32% 39.02% 41.46% 0.00% 0.00% 0.00% 22.46% 0.00% 0.00% 0.00%
EBITDA Margin		 -152.61% -141.88% -125.73% -222.76% 0.00% 0.00% 0.00% -239.30% 0.00% 0.00% 0.00%
Operating Margin		 -153.18% -156.58% -138.72% -198.46% 0.00% 0.00% 0.00% -258.57% 0.00% 0.00% 0.00%
EBIT Margin		 -157.28% -153.72% -137.19% -234.37% 0.00% 0.00% 0.00% -258.57% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -146.93% -151.02% -132.68% -231.63% 0.00% 0.00% 0.00% -247.29% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.37% 100.00% 100.00% 102.61% 75.45% 94.35% 100.00% 106.25% 120.99% 116.83%
Interest Burden Percent		 93.41% 97.88% 96.71% 98.83% 99.21% 97.87% 95.13% 95.64% 98.32% 99.77% 99.29%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -165.90% -157.85% -145.43% -167.18% 0.00% 0.00% 0.00% -240.16% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -160.15% -150.72% -137.50% -148.31% 0.00% 0.00% 0.00% -228.04% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 110.58% 105.53% 86.83% 85.47% 0.00% 0.00% 0.00% 129.81% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -55.32% -52.32% -58.60% -81.70% 0.00% -72.10% -82.17% -110.34% 0.00% -173.14% -253.38%
Cash Return on Invested Capital (CROIC)		 -177.12% -181.10% -184.64% -118.22% -110.39% -176.52% -148.77% -145.46% -188.73% 0.00% 0.00%
Operating Return on Assets (OROA)		 -63.00% -54.51% -63.65% -95.34% 0.00% 0.00% 0.00% -118.34% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -58.85% -53.56% -61.56% -94.22% 0.00% 0.00% 0.00% -113.18% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -55.32% -52.32% -58.60% -81.70% 0.00% -72.10% -82.17% -110.34% 0.00% -173.14% -253.38%
Return on Equity Simple (ROE_SIMPLE)		 -54.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.26 -1.41 -1.23 -1.54 -1.44 -1.72 -1.35 -1.48 -1.97 -3.43 -1.41
NOPAT Margin		 -107.22% -109.60% -97.10% -138.92% 0.00% 0.00% 0.00% -181.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.74% -7.13% -7.93% -18.87% -12.98% -0.79% -5.54% -12.11% -22.33% -33.46% -17.96%
Return On Investment Capital (ROIC_SIMPLE)		 -10.33% -14.28% -12.99% -21.66% -18.34% -12.50% -11.41% -14.67% -26.96% -319.50% 117.27%
Cost of Revenue to Revenue		 75.31% 63.68% 60.98% 58.54% 0.00% 0.00% 0.00% 77.54% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 117.18% 137.28% 118.05% 154.61% 0.00% 0.00% 0.00% 197.65% 0.00% 0.00% 0.00%
R&D to Revenue		 56.01% 51.35% 55.36% 80.52% 0.00% 0.00% 0.00% 76.89% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 177.86% 192.90% 177.73% 239.92% 0.00% 0.00% 0.00% 281.02% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.84 -1.97 -1.73 -2.61 -2.08 -2.42 -1.92 -2.12 -2.84 -4.84 -2.01
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.79 -1.82 -1.59 -2.48 -1.95 -2.29 -1.77 -1.96 -2.71 -4.58 -1.79
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.20 0.17 0.00 0.00 0.32 0.24 0.75 0.00 0.38 6.00 0.00
Price to Tangible Book Value (P/TBV)		 0.24 0.22 0.00 0.00 0.42 0.27 0.87 0.00 0.48 6.00 0.00
Price to Revenue (P/Rev)		 0.39 0.35 0.00 0.00 0.62 0.00 0.00 0.00 0.58 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.10 0.07 0.13 0.15 0.12 0.02 0.02 0.06 0.06 0.00 0.00
Long-Term Debt to Equity		 0.07 0.07 0.08 0.09 0.06 0.02 0.02 0.01 0.00 0.00 0.00
Financial Leverage		 -0.69 -0.70 -0.63 -0.58 -0.58 -0.80 -0.69 -0.57 -0.64 -0.99 -0.99
Leverage Ratio		 1.20 1.22 1.19 1.25 1.25 1.21 1.19 1.25 1.32 1.28 1.41
Compound Leverage Factor		 1.12 1.19 1.15 1.24 1.24 1.18 1.13 1.19 1.30 1.28 1.40
Debt to Total Capital		 8.79% 6.55% 11.19% 13.31% 10.78% 2.23% 1.83% 5.26% 5.75% 0.00% 0.00%
Short-Term Debt to Total Capital		 2.84% 0.00% 4.49% 5.89% 5.45% 0.00% 0.00% 4.03% 5.33% 0.00% 0.00%
Long-Term Debt to Total Capital		 5.96% 6.55% 6.70% 7.42% 5.33% 2.23% 1.83% 1.22% 0.42% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.21% 93.45% 88.81% 86.69% 89.22% 97.77% 98.17% 94.74% 94.25% 100.00% 100.00%
Debt to EBITDA		 -0.18 -0.09 -0.16 -0.12 -0.11 -0.04 -0.03 -0.07 -0.05 0.00 0.00
Net Debt to EBITDA		 1.09 0.79 0.69 0.32 0.49 1.26 1.13 0.88 0.59 0.00 0.00
Long-Term Debt to EBITDA		 -0.12 -0.09 -0.10 -0.07 -0.05 -0.04 -0.03 -0.02 0.00 0.00 0.00
Debt to NOPAT		 -0.23 -0.11 -0.21 -0.17 -0.15 -0.05 -0.04 -0.10 -0.07 0.00 0.00
Net Debt to NOPAT		 1.41 1.05 0.90 0.46 0.69 1.77 1.51 1.18 0.79 0.00 0.00
Long-Term Debt to NOPAT		 -0.16 -0.11 -0.12 -0.10 -0.07 -0.05 -0.04 -0.02 -0.01 0.00 0.00
Altman Z-Score		 -9.91 -12.03 0.00 0.00 -16.57 -9.31 -9.27 0.00 -18.22 -63.17 -146.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.58 4.41 5.07 3.05 3.49 6.99 6.95 5.94 3.12 1.37 0.50
Quick Ratio		 5.14 3.53 4.12 2.08 2.77 5.86 6.25 4.85 2.35 1.14 0.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.05 -1.49 -2.26 -0.86 -0.06 0.15 0.05 -0.94 -0.67 -0.84 3.36
Operating Cash Flow to CapEx		 -96,716,100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.40 0.35 0.46 0.41 0.32 0.00 0.00 0.46 0.49 0.00 0.00
Accounts Receivable Turnover		 29.77 15.00 22.02 15.21 12.72 0.00 0.00 20.23 0.00 0.00 0.00
Inventory Turnover		 3.17 2.44 2.88 3.38 2.23 0.00 0.00 3.09 0.00 0.00 0.00
Fixed Asset Turnover		 5.30 4.66 5.07 3.56 2.95 0.00 0.00 4.52 5.15 0.00 0.00
Accounts Payable Turnover		 2.65 2.14 3.29 2.35 1.73 0.00 0.00 2.59 2.62 0.00 0.00
Days Sales Outstanding (DSO)		 12.26 24.34 16.58 24.00 28.70 0.00 0.00 18.04 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 115.23 149.30 126.78 108.03 163.66 0.00 0.00 118.21 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 137.57 170.28 110.87 155.42 211.35 0.00 0.00 140.79 139.53 0.00 0.00
Cash Conversion Cycle (CCC)		 -10.08 3.36 32.49 -23.39 -18.99 0.00 0.00 -4.54 -139.53 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 4.53 3.24 3.83 3.67 3.15 1.37 2.43 3.12 1.85 -1.23 -2.33
Invested Capital Turnover		 1.55 1.44 1.50 1.20 0.95 0.00 0.00 1.33 1.80 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.79 0.09 1.03 -0.69 -1.38 -1.87 -1.40 -0.55 -1.30 -2.59 -4.77
Enterprise Value (EV)		 -4.37 -4.36 0.00 0.00 -1.60 -7.31 -0.50 0.00 -2.17 4.22 6.34
Market Capitalization		 2.20 1.61 0.00 0.00 2.27 3.17 8.66 0.00 2.61 6.45 7.47
Book Value per Share		 $1.83 $24.16 $13.54 $8.75 $6.41 $13.77 $2.93 $2.42 $1.70 $0.26 ($0.22)
Tangible Book Value per Share		 $1.53 $19.48 $10.73 $6.34 $4.89 $12.11 $2.53 $2.04 $1.33 $0.26 ($0.22)
Total Capital		 12 9.85 9.45 7.13 7.87 14 12 10 7.31 1.08 -1.20
Total Debt		 1.07 0.64 1.06 0.95 0.85 0.31 0.22 0.53 0.42 0.00 0.00
Total Long-Term Debt		 0.73 0.64 0.63 0.53 0.42 0.31 0.22 0.12 0.03 0.00 0.00
Net Debt		 -6.57 -5.97 -4.57 -2.51 -3.87 -10 -9.16 -6.47 -4.78 -2.23 -1.13
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.24 0.10 0.64 0.64 0.28 0.24 -0.13 0.72 -0.13 -1.51 -2.38
Debt-free Net Working Capital (DFNWC)		 8.88 6.72 6.27 4.10 5.00 11 9.24 7.72 5.07 0.72 -1.24
Net Working Capital (NWC)		 8.54 6.72 5.84 3.68 4.57 11 9.24 7.31 4.68 0.72 -1.24
Net Nonoperating Expense (NNE)		 0.47 0.53 0.45 1.03 0.68 0.07 0.38 0.54 0.99 2.40 0.92
Net Nonoperating Obligations (NNO)		 -6.57 -5.97 -4.57 -2.51 -3.87 -12 -9.16 -6.47 -5.04 -2.30 -1.13
Total Depreciation and Amortization (D&A)		 0.05 0.15 0.14 0.13 0.13 0.13 0.16 0.16 0.13 0.26 0.22
Debt-free, Cash-free Net Working Capital to Revenue		 21.99% 2.24% 12.94% 13.22% 7.65% 0.00% 0.00% 15.96% -2.98% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 157.86% 146.11% 126.36% 84.83% 136.64% 0.00% 0.00% 171.23% 112.42% 0.00% 0.00%
Net Working Capital to Revenue		 151.72% 146.11% 117.81% 76.14% 124.91% 0.00% 0.00% 162.18% 103.78% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.60) ($101.80) ($54.20) ($3.64) ($1.94) ($1.83) ($0.44) ($0.51) ($0.73) ($1.51) ($0.42)
Adjusted Weighted Average Basic Shares Outstanding		 480.65K 19.05K 31.01K 706.55K 1.10M 975.90K 3.95M 3.95M 4.05M 4.16M 5.47M
Adjusted Diluted Earnings per Share		 $0.00 ($101.80) ($54.20) ($3.64) ($1.94) ($1.83) ($0.44) ($0.51) ($0.73) ($1.51) ($0.42)
Adjusted Weighted Average Diluted Shares Outstanding		 417.90K 19.05K 31.01K 706.55K 1.10M 975.90K 3.95M 3.95M 4.05M 4.16M 5.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($101.80) $0.00 $0.00 $0.00 ($1.83) $0.00 $0.00 $0.00 ($1.51) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 417.90K 0.00 35.90K 1.21M 1.21M 2.38M 2.80M 2.92M 3.31M 5.49M 5.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.26 -1.41 -1.23 -1.54 -1.44 -1.72 -1.35 -1.48 -1.97 -3.43 -1.41
Normalized NOPAT Margin		 -107.22% -109.60% -97.10% -138.92% 0.00% 0.00% 0.00% -181.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -146.93% -150.47% -132.68% -231.63% 0.00% 0.00% 0.00% -247.29% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -7.32% 0.00% 0.00% 0.00% -10.83% -10.10% -10.07% -8.89% -1.09% 0.00%

Financials Breakdown Chart

Key Financial Trends

InMed Pharmaceuticals’ latest quarter shows lower expenses and a slower cash outflow than several recent quarters, but the company remains unprofitable and its liquidity position has weakened sharply. Figures below are in U.S. dollars.

  • Operating expenses declined. Q1 fiscal 2027 operating expenses were about $2.0 million, down from $2.8 million in Q3 fiscal 2026 and $4.3 million in Q4 fiscal 2026. The latest quarter’s research and development expense also fell to about $206,000 from roughly $1.0 million in Q3.
  • Quarterly operating cash burn eased. Cash used in operating activities was about $1.1 million in Q1 fiscal 2027, compared with $1.7 million in Q3 and $3.0 million in Q4 fiscal 2026.
  • Recent results are not fully comparable. The Q4 fiscal 2026 income statement is marked calculated and reports negative revenue, while several periods also include results from discontinued operations. These factors complicate quarter-to-quarter comparisons.
  • Revenue was zero in the latest quarter. InMed reported no revenue in Q1 fiscal 2027, following $820,000 in Q2 fiscal 2026. Several other recent quarters also reported no revenue, leaving the company reliant on its cash resources and financing while it records operating costs.
  • Losses remain substantial. The company reported a consolidated net loss of about $2.3 million in Q1 fiscal 2027, including a $2.0 million loss from continuing operations. Losses from continuing operations have recurred across the periods provided.
  • Cash and assets have fallen considerably. Cash and equivalents declined from $5.2 million at March 31, 2026, to $1.1 million at September 30, 2026. Total assets fell from $9.1 million to $1.3 million over the same period.
  • Current liabilities exceed current assets. At September 30, 2026, current assets were about $1.3 million versus current liabilities of $2.5 million, including $2.5 million in accounts payable. Total shareholders’ equity was negative by about $1.2 million.
  • Cash runway appears limited. Cash and short-term investments totaled about $1.1 million at quarter-end, close to the $1.1 million used in operating activities during the quarter. Continued cash burn at that pace could make additional financing or other liquidity measures important.
11/11/26 07:07 AM ETAI Generated. May Contain Errors.

Mentari Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mentari Therapeutics' financial year ends in June. Their financial year 2026 ended on June 30, 2026.

Mentari Therapeutics had net income of -$12.56 million at the end of 2026, a 53.9% decrease from 2025, and a 40.5% decrease since 2020. View Mentari Therapeutics' forecast to see where analysts expect Mentari Therapeutics to go next.

Mentari Therapeutics' total operating income in 2026 was -$11.61 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.61 million

Over the last 6 years, Mentari Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2026, a change of 0.0%.

In the past 11 quarters, Mentari Therapeutics' cash and equivalents has ranged from $1.09 million in Q1 2027 to $9.53 million in Q2 2024, and is currently $1.09 million as of their latest financial filing in Q1 2027.

Mentari Therapeutics had total debt of $0.00 at the end of 2026, a 100.0% decrease from 2025, and none in 2020.

Over the last 6 years, Mentari Therapeutics' book value per share changed from 1.13 in 2020 to 0.26 in 2026, a change of -77.1%.



Financial statements for NASDAQ:MTRI last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Inside Nevada's 60 Million Ounce Gold Corridor
Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...
Wall Street Logic | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...
Behind the Markets | Sponsoredtc pixel
Trump compared today's market to 1929
President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...
USA Capital Gold | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel